Astria Therapeutics Says STAR-0310 Showed Half-Life of 68 Days in Phase 1a Trial; Shares Up Pre-Bell
MT Newswires Live
Yesterday
Astria Therapeutics (ATXS) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.
Shares of the company were up more than 4% in recent Wednesday premarket activity.
The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.
STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.
Price: 7.60, Change: +0.33, Percent Change: +4.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.